Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers

Hannes Vietzen (), Laura M. Kühner, Sarah M. Berger, Markus Ponleitner, Marianne Graninger, Charlotte Pistorius, Christof Jungbauer, Markus Reindl, Henrieke Saucke, Franziska Kauth, Eva-Maria Wendel, Kevin Rostásy, Markus Breu, Barbara Kornek, Gabriel Bsteh, Thomas Berger, Paulus Rommer and Elisabeth Puchhammer-Stöckl
Additional contact information
Hannes Vietzen: Medical University of Vienna
Laura M. Kühner: Medical University of Vienna
Sarah M. Berger: Medical University of Vienna
Markus Ponleitner: Medical University of Vienna
Marianne Graninger: Medical University of Vienna
Charlotte Pistorius: Lower Austria and Burgenland
Christof Jungbauer: Lower Austria and Burgenland
Markus Reindl: Medical University of Innsbruck
Henrieke Saucke: University Witten/ Herdecke
Franziska Kauth: University Witten/ Herdecke
Eva-Maria Wendel: Olgahospital
Kevin Rostásy: University Witten/ Herdecke
Markus Breu: Medical University of Vienna
Barbara Kornek: Medical University of Vienna
Gabriel Bsteh: Medical University of Vienna
Thomas Berger: Medical University of Vienna
Paulus Rommer: Medical University of Vienna
Elisabeth Puchhammer-Stöckl: Medical University of Vienna

Nature Communications, 2025, vol. 16, issue 1, 1-11

Abstract: Abstract Multiple sclerosis (MS) is an immune-mediated demyelinating disease. Epstein-Barr virus (EBV) encodes for the EBNA-1381-452 region that induces autoreactive antibody responses, which are likely critically involved in MS pathogenesis. Here we investigate whether these EBNA-1381-452-specific antibodies can serve as a biomarker to identify at-risk individuals for MS. We quantify EBNA-1381-452-specific antibody titers from 324 relapsing-remitting MS patients and 324 matched controls in longitudinal follow-up plasma samples, starting from the individual’s EBV-seroconversion. In MS patients, significantly elevated EBNA-1381-452-specific IgG titers are identified that are increased already as early as nine months after EBV-seroconversion (OR:5.7; 95% CI: 4.1-8.1; P

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-61751-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-61751-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-61751-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().